Still's Disease Market Epidemiology Report 2025-2035 | Drug Pipeline, Therapies, and Regional Outlook

According to the IMARC Group, the Still's disease market size reached a value of USD 1.33 billion in 2024. Looking forward, the 7MM is expected to reach USD 1.92 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 3.41% during 2025-2035.

With the rising awareness of Still's Disease, along with improvements in diagnostic technology testing and an increase in the availability of targeted therapy, there is an exceptional growth opportunity in the year 2025. Still's Disease, or systemic onset juvenile idiopathic arthritis (sJIA) when it develops in children, and adult-onset Still's Disease (AOSD) in adults, is a rare inflammatory disorder characterized by high fevers, arthralgia, rash, and increased inflammatory markers.

A rise in diagnostic cases is one of the significant factors driving the other Still's Disease market growth, in part due to enhanced diagnostic capabilities. In recognition of early symptoms, the help of advanced state-of-the-art diagnostic blood tests and imaging technologies can actually facilitate clinicians to diagnose Still's Disease with much greater accuracy. This holds true in diagnosing those more complicated instances or overlapping cases, where diagnosis used to be rather ambiguous.

Besides this, the demand for successful therapy is driving the creation and commercialization of newer medications. Corticosteroids and NSAIDs have been in vogue for long as the standard for treatment to manage inflammation and symptoms, but prolonged administration of corticosteroids and NSAIDs usually have unwanted effects. Therefore, biologic therapies against specific disease pathways like IL-1 and IL-6 inhibitors are becoming increasingly popular. The growing application of drugs like anakinra, canakinumab, and tocilizumab is actually remodeling treatment alternatives.

In addition, increased focus on personalized medicine is another enormous trend favoring the pharma sector. Today, doctors are individualizing therapeutic regimens based on patient profiles, disease intensity, and genetic factors to achieve improved results with reduced side effects. This shift toward personalized medicine is also prompting pharmaceutical firms to emphasize biomarker and drug research.

Request for a sample of this report: https://www.imarcgroup.com/stills-disease-market/requestsample

This report also provides a detailed analysis of the current Still's disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Still's disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Still's disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape with key players:

The competitive landscape of the Still's disease market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Genentech
2. Novartis
3. Swedish Orphan Biovitrum

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145